CRP Serum Whole Blood Rapid Test (Cassette)

Name: CRP Serum Whole Blood Rapid Test (Cassette)
SKU: DTS233
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

serum/whole blood

Intended Use

C-reactive protein (CRP) is an acute phase protein, synthesis by the liver cells. C-Reactive Protein (CRP) Rapid Test Kit is based on the principle of colloidal gold immunochromatographic assay, qualitative detection of CRP abnormality in wholeblood, serum or plasma, as an aid of clinical diagnosis of CRP. This one step test is very sensitive and only takes about 10 minutes. Test results are read visually without any instrument.

Storage

Store the test device at 4 to 30°C. Do Not Freeze.

Citations

Have you cited DTS233 in a publication? Let us know and earn a reward for your research.

Accuracy of commercially available c-reactive protein rapid tests in the context of undifferentiated fevers in rural Laos

Koukeo Phommasone, Thomas Althaus, Phonesavanh Souvanthong, Khansoudaphone Phakhounthong, Laxoy Soyvienvong, Phatthaphone Malapheth, Mayfong Mayxay, Rebecca L Pavlicek, Daniel H Paris, David Dance, Paul Newton, Yoel Lubell

BMC Infect Dis2016 FebPubMed ID: 26846919Read Article

Applications: IA
Reactive species: Human
"Abstract: C-Reactive Protein (CRP) has been shown to be an accurate biomarker for discriminating bacterial from viral infections in febrile patients in Southeast Asia. Here we investigate the accuracy of existing rapid qualitative and semi-quantitative tests as compared with a quantitative reference test to assess their potential for use in remote tropical settings."
Article snippet: In each site one of the three CRP RDTs and the reference test was performed at point-of-care immediately after patient presentation. Two of the sites used serum for both the RDT and the reference test (DTS233, Creative Diagnostics, USA; *).

Distribution of the levels of CRP in the three sites. (Koukeo Phommasone, <i>et al</i>, 2016)

Figure 1. Distribution of CRP levels in the three sites

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Associations of C-reactive protein and fibrinogen with mortality from all-causes, cardiovascular disease and cancer among US adults

PREVENTIVE MEDICINE

Authors: Liu, Junxiu; Zhang, Yanan; Lavie, Carl J.; Tabung, Fred K.; Xu, Jiting; Hu, Qingwei; He, Lixia; Zhang, Yunxiang

Abstract

C-reactive protein (CRP) and fibrinogen are associated with an increased risk of death with suggested differences by gender, diet quality and race/ethnicity. However, the current evidence is limited. We used data including 8646 men and 9880 women from the National Health and Nutrition Examination Survey (NHANES) Linked Morality cohort (1999-2011) to investigate the associations of CRP and fibrinogen with mortality overall and by gender, race/ethnicity and diet quality. Cox-proportional hazard model was used to quantify the associations. With a median follow-up of 6 years, a strong dose-response relationship was observed between CRP levels and mortality risk in men after multivariable adjustment. For subjects who survived the first two years, the adjusted hazard ratios (HRs) for total mortality across quartiles (from lower to higher) of CRP were 1.97 (95% CI: 0.62-6.33), 1.89 (0.59, 6.06) and 6.34 (2.28-17.7) (P for trend < 0.001). For cardiovascular disease (CVD) mortality, its association with CRP varied by diet quality. For cancer mortality, its association differed by history of cancer, and positive associations were observed only among subjects with history of cancer. In contrast, no such association of CRP with mortality was found in women. For fibrinogen, we observed its positive association with total mortality and the HRs across quartiles of fibrinogen (from lower to higher) were 1.21 (0.88, 1.67), 1.49 (1.22, 1.82) and 1.99 (1.56, 2.55). The association with CVD mortality differed by diet quality whereas no association was found with cancer mortality. Our findings suggest that higher levels of CRP and fibrinogen were associated with lower survival from total and CVD; the associations of CRP with mortality were more pronounced in men than women. Diet quality is an effect modifier for the association of CRP and fibrinogen with CVD mortality.

Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study

EXPERT REVIEW OF RESPIRATORY MEDICINE

Authors: Chen, Jing; Lin, Shaowu; Niu, Conway; Xiao, Qi

Abstract

Objective: To understand the clinical effectiveness and safety of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19. Methods: A retrospective cohort study was used to analyze the case data of 200 inpatients diagnosed with common-type COVID-19 at Wuhan Hospital. Participants were divided into a control group and an experimental group. The control group was treated with Arbidol hydrochloride capsules while the experimental group was treated with combination Arbidol hydrochloride capsules and Shufeng Jiedu Capsules (SFJDC) for 14 days. Results: Defervescence was achieved more rapidly in the experimental group (P< 0.05). The white blood cell count and the lymphocyte percentage in the experimental group were higher than that of the control group (P< 0.05). CRP and IL-6 levels in the experimental group were significantly lower than those in the control group (P< 0.05). The proportion of chest CT studies showing resolution of pneumonia in the experimental group was significantly higher than that in the control group (P< 0.05). Conclusions: A treatment regimen of Shufeng Jiedu Capsules combined with Arbidol to treat common-type COVID-19, combining traditional Chinese and western allopathic medicine, improves time to recovery, has better clinical effectiveness, and is safe.